Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections.

Alosaimy, Sara; Jorgensen, Sarah C J; Lagnf, Abdalhamid M; Melvin, Sarah; Mynatt, Ryan P; Carlson, Travis J; Garey, Kevin W; Allen, David; Venugopalan, Veena; Veve, Michael; Athans, Vasilios; Saw, Stephen; Yost, Christine N; Davis, Susan L; Rybak, Michael J

Alosaimy, Sara; Jorgensen, Sarah C J; Lagnf, Abdalhamid M; Melvin, Sarah; Mynatt, Ryan P; Carlson, Travis J; Garey, Kevin W; Allen, David; Venugopalan, Veena; Veve, Michael; Athans, Vasilios; Saw, Stephen; Yost, Christine N; Davis, Susan L; Rybak, Michael J.

Afiliación

Alosaimy S; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Jorgensen SCJ; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Lagnf AM; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Melvin S; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Mynatt RP; Department of Pharmacy Services, Detroit Medical Center, Detroit, Michigan, USA.
Carlson TJ; College of Pharmacy, University of Houston, Houston, Texas, USA.
Garey KW; College of Pharmacy, University of Houston, Houston, Texas, USA.
Allen D; Department of Pharmacy, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
Venugopalan V; College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Veve M; College of Pharmacy, University of Tennessee, Knoxville, Tennessee, USA.
Athans V; University of Tennessee Medical Center, Knoxville, Tennessee, USA.
Saw S; Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Yost CN; Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Davis SL; Beaumont Hospital, Royal Oak, Michigan, USA.
Rybak MJ; Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

Open Forum Infect Dis ; 7(3): ofaa051, 2020 Mar.

Article en En | MEDLINE | ID: mdl-32161775

ABSTRACT

ABSTRACT

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

Palabras clave

Gram-negative infections; carbapenem-resistant Enterobacteriaceae; meropenem-vaborbactam; multidrug-resistant

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Open Forum Infect Dis Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos